Navigation Links
Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
Date:2/20/2008

reflects the ongoing effort of all our employees, we will continue to focus on improving our profitability," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "Secondly, our domestic epilepsy business is growing, as evidenced by a 9% growth in units sold, and revenue growth of approximately 13%, over the third quarter of FY07. We continue to enjoy strong growth in our international business, which delivered 34% growth in epilepsy revenue. Globally, epilepsy revenue grew by 17% over the prior year. While our January price increase had little impact on the recently completed quarter, we expect it to contribute more significantly in future periods.

"After consulting with clinical and reimbursement experts, we have developed a plan for our depression indication. We have also engaged an investment bank to find a financial partner to assist in execution of the plan, which includes the possible transfer of the depression indication to a separate entity in which we expect to maintain at least a minority interest.

"The licensing activity that we announced in December is a clear indication of our progress toward our fourth objective. We intend to continue to seek appropriate partnership opportunities.

"Our balance sheet, particularly our cash position, has improved over the course of the year, and at the appropriate time, will provide management with resources to enhance the value of the company to shareholders.

"The share repurchase program underscores our ongoing commitment to increase shareholder value and the Board's confidence that we are poised for future growth. Overall, we made solid progress on all fronts, strengthening the company's position in the neuromodulation device business sector. We expect this progress to continue."

Additional details of progress toward objectives and sales by geography, indication, and product line will be provided during the upcoming conference call and in the accompanying presenta
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Cyberonics Licenses Obesity-Related Patents
2. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 31, 2014 Fundraising support for ... greater gains than losses. At noon on Monday, November 10 ... Hospital (SSMH), greater than 20 Susquehanna Health (SH) employees ... to raise awareness and funds for the new Cancer Center ... participants’ heads for this act of love and support to ...
(Date:10/31/2014)... for Healthy Neighborhoods (PRCHN) at Case Western Reserve ... in nearly $13.32 million in federal grants awarded ... The Centers for Disease Control and Prevention (CDC) ... five years. The funds will support the center,s ... environmental, and policy interventions that prevent and reduce ...
(Date:10/31/2014)... Monica Williams-Murphy MD , advanced care planning ... chaos that can occur for people who have not ... Americans who come into the emergency department facing the ... the moment and so are their families." She adds, ... catalyst for a family to get the critical conversations ...
(Date:10/31/2014)... 31, 2014 Activz Whole-Food Nutrition ... Silver line offering natural silver healing support† in ... a century, silver has been used to support natural ... products is the most advanced version available. This latest ... chemical structure that supports the existing healing mechanisms in ...
(Date:10/31/2014)... increases the risk of certain types of breast cancer ... studies show. One study of more than 3,200 ... risk for estrogen receptor-negative and progesterone receptor-positive breast tumors ... long time for white women, but now we are ... John, a senior research scientist at the Cancer Prevention ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2
... exercised during pregnancy needed less pain meds, study found ... during pregnancy reduces the amount of pain-killing medication requested ... that included 71 expectant mothers. , Half the ... week of aquarobics during their pregnancy, while the other ...
... the Dallas office of WHR Architects. Ms. Moran, nationally recognized ... Education, Science and Technology practice and broaden the talent base ... , "Anita,s experience and skills complement ... college and university clients," said Mark W. Vaughan AIA, ACHA, ...
... SPRINGFIELD, Mass., Nov. 21 Massachusetts Mutual Life,Insurance ... two,Co-Chief Operating Officers. , ... Officer, Executive Vice President,and Chief Investment Officer, will ... H. Reese, who remains Chairman and Chief Executive,Officer. ...
... NXTM ), a leading manufacturer of innovative ... 2008 Technology Fast 500, a,ranking of the 500 fastest ... America. Rankings are based on percentage of,fiscal year revenue ... more than 20,000 percent during this period. , ...
... by HIV/AIDS in New Jersey and Africa - , ... than 800 local Roche employees are participating in the ... support children infected and affected by HIV/AIDS in New Jersey and ... through the township of Nutley, collect donations for their efforts, and ...
... to take, has fewer side effects than chemotherapy, ... The cancer-fighting pill Iressa works as well as chemotherapy ... , Although neither therapy prolongs survival beyond eight months, ... be a better choice for patients who did not ...
Cached Medicine News:Health News:Aquarobics May Help Ease Labor 2Health News:Anita Moran AIA Joins WHR Dallas 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 2Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 3Health News:Roche Holds Sixth Annual Children's Walk in Nutley 2Health News:Roche Holds Sixth Annual Children's Walk in Nutley 3Health News:Roche Holds Sixth Annual Children's Walk in Nutley 4Health News:Iressa as Good as Chemotherapy for Lung Cancer 2Health News:Iressa as Good as Chemotherapy for Lung Cancer 3
(Date:10/31/2014)... Mich. , Oct. 31, 2014  Lycera ... modulators to treat autoimmune disease and cancer, today ... novel synthetic RORgamma agonist product candidates will be ... for Immunotherapy of Cancer (SITC) being held November ... Convention Center, National Harbor, MD.  The poster, entitled ...
(Date:10/31/2014)... -- British Journal of Urology International ... "male orgasmic dysfunction" with their doctor prior to any ... while preserving sexual function     ... paper in the British Journal of Urology International which ... with their doctors the likely impact of treatment options ...
(Date:10/31/2014)... DUBLIN , October 30, 2014 ... ) has announced the addition of the  "Process ...  conference to their offering.      (Logo: ... , Science and Risk Based Approach to Process ... Quality Risk Management FDA Process Validation ...
Breaking Medicine Technology:Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... 29, 2010 Reportlinker.com announces that a new ... 2010-2015 In-depth Research Report on ... http://www.reportlinker.com/p0356862/2010-2015-In-depth-Research-Report-on-China-Sodium-Fluoride-Industry.html Report SummaryBased on ... Bureau, General Administration of Custom, Ministry of Commerce ...
... Reportlinker.com announces that a new market research report ... The Outlook for Pharmaceuticals to 2012 ... Pharmaceuticals to 2012 is a new collection of management ... individual and highly-detailed analysis of each market, looking at ...
Cached Medicine Technology:Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 2Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 3Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 4Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 5
Toxoplasma IgM II ELISA....
HSV 1 & HSV 2 DFA Test....
Herpes Simplex Virus 2 IgG ELISA....
Herpes Simplex Virus 1 IgG ELISA....
Medicine Products: